Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

Celgene building

Celgene gains French reimbursement for Revlimid in multiple myeloma

HAS decides it offers ' significant improvement' over existing treatments

- PMLiVE

Amgen hopes its latest Kyprolis trial hits the mark with regulators

A.R.R.O.W study takes aim at once-weekly dosing regimen in multiple myeloma

- PMLiVE

SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

Will now recommend the first-in-class treatment after securing a discount

Celgene building

Celgene steps back from $1bn Sutro acquisition

Instead opts for amended licensing deal with US biotech

Celgene building

Celgene, Agios get FDA OK for leukaemia drug Idhifa

Duo’s drug becomes first new AML therapy since Novartis' Rydapt

- PMLiVE

Amgen aspires to new Kyprolis label in the US and Europe

Appeals to regulators to add survival data to multiple myeloma drug's labelling

Celgene building

Celgene joins PD-1 race via partnership with BeiGene

The pharma giant will pay the Chinese firm up to $980m in milestone payments

- PMLiVE

Juno gives up on lead CAR-T drug after deaths

ROCKET trial for leukaemia patients ended

Celgene building

Celgene bags US priority review for cancer metabolism drug

First approval for enasidenib could be just six months away

- PMLiVE

Celgene’s president and COO to retire

Scott Smith set to succeed Dr Jacqualyn Fouse from 1 April

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links